A Pilot Dose-Escalation Safety Study of Tenecteplase in Acute Ischemic Stroke
- 1 March 2005
- journal article
- Published by Wolters Kluwer Health in Stroke
- Vol. 36 (3) , 607-612
- https://doi.org/10.1161/01.str.0000154872.73240.e9
Abstract
Background and Purpose— Recombinant tissue-type plasminogen activator (rtPA) is the only approved treatment in acute ischemic stroke. However, intracerebral hemorrhage (ICH) occurs in 6.4% of patients treated with rtPA and limits its use. Tenecteplase (TNK) is a modified form of rtPA, with longer half-life and greater fibrin specificity. Patients after myocardial infarction had fewer systemic hemorrhages when treated with TNK compared with rtPA. This open-label, dose-escalation safety study was conducted to develop initial experience with TNK in the treatment of ischemic stroke.Keywords
This publication has 8 references indexed in Scilit:
- Predicting Major Neurological Improvement With Intravenous Recombinant Tissue Plasminogen Activator Treatment of StrokeStroke, 2004
- StrokeThe Lancet, 2003
- Pharmacokinetics and Pharmacodynamics of Tenecteplase in Fibrinolytic Therapy of Acute Myocardial InfarctionClinical Pharmacokinetics, 2002
- Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trialThe Lancet, 1999
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric StrokeJAMA, 1995
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993
- Observer variability in assessing impaired consciousness and coma.Journal of Neurology, Neurosurgery & Psychiatry, 1978